Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLDOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This randomized, placebo-controlled trial examined whether resistant starch (RS), a prebiotic, has therapeutic effects in metabolic dysfunction-associated steatotic liver disease (MASLD). The researchers focused on why RS efficacy was heterogeneous, since about 30% of participants showed limited benefit. Using multi-omics analysis, fecal microbiota transplantation, population stratification, network analysis, and in vitro and in vivo experiments, they sought the microbial basis of this variable response. They then built a predictive model combining baseline microbial and clinical features to forecast who would respond.
Who was studied?
Participants were drawn from the original randomized, placebo-controlled trial of resistant starch in MASLD, with the finding of heterogeneous response replicated in a separate multi-center trial (ChiCTR2300074588). The abstract does not give exact participant numbers or demographic details for either trial. A strain, Bifidobacterium pseudocatenulatum RRP01, was isolated from the study cohort for further experimentation.
What were the most important findings?
Baseline gut microbiota composition was the dominant contributor to whether a participant responded to resistant starch. Prevotella was identified as a key cause of low response because it inhibits RS-degrading bacteria, impairing RS utilization. In contrast, the cohort-derived strain Bifidobacterium pseudocatenulatum RRP01 restored RS degradation and improved the RS response that Prevotella had attenuated. A predictive model integrating baseline microbial and clinical features achieved an area under the curve of 0.74 to 0.87 for stratifying likely responders.
What are the greatest implications of this study?
The findings show that pre-existing gut microbiota composition, not just the intervention itself, determines whether resistant starch benefits patients with MASLD. This supports moving toward microbiota-oriented precision therapeutics, where baseline microbial and clinical features are used to predict who will respond before treatment begins. It also points to specific microbiota-targeted strategies, such as supplementing Bifidobacterium pseudocatenulatum RRP01, to overcome Prevotella-driven non-response and expand the benefit of prebiotic therapy to more patients.